Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Stock Competitors & Peer Comparison
See MDGL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MDGL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDGL | $534.49 | +0.26% | 12.3B | -41.76 | -$12.80 | N/A |
| VRTX | $515.44 | +0.17% | 130.8B | 27.09 | $19.03 | N/A |
| REGN | $781.49 | -1.48% | 80.5B | 17.13 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $984.39 | +0.04% | 61.2B | 88.84 | $11.08 | N/A |
| MRNA | $143.97 | +5.38% | 57.1B | -17.67 | -$8.15 | N/A |
| RVMDW | $11.29 | +2.08% | 44.2B | -1.28 | -$8.82 | N/A |
| RVMD | $203.77 | +0.21% | 43.3B | -23.10 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $346.51 | +1.38% | 37B | 61.01 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
MDGL vs VRTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, VRTX has a market cap of 130.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while VRTX trades at $515.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas VRTX's P/E ratio is 27.09. In terms of profitability, MDGL's ROE is -0.57%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, MDGL is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
MDGL vs REGN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while REGN trades at $781.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas REGN's P/E ratio is 17.13. In terms of profitability, MDGL's ROE is -0.57%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MDGL is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
MDGL vs VRNA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MDGL's ROE is -0.57%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MDGL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
MDGL vs ARGX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ARGX has a market cap of 61.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ARGX trades at $984.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ARGX's P/E ratio is 88.84. In terms of profitability, MDGL's ROE is -0.57%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, MDGL is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
MDGL vs MRNA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MRNA has a market cap of 57.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MRNA trades at $143.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MRNA's P/E ratio is -17.67. In terms of profitability, MDGL's ROE is -0.57%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, MDGL is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
MDGL vs RVMDW Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RVMDW has a market cap of 44.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RVMDW trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, MDGL's ROE is -0.57%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, MDGL is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
MDGL vs RVMD Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RVMD trades at $203.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RVMD's P/E ratio is -23.10. In terms of profitability, MDGL's ROE is -0.57%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, MDGL is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
MDGL vs SGEN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MDGL's ROE is -0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MDGL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
MDGL vs ONC Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ONC has a market cap of 37B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ONC trades at $346.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ONC's P/E ratio is 61.01. In terms of profitability, MDGL's ROE is -0.57%, compared to ONC's ROE of +0.14%. Regarding short-term risk, MDGL is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
MDGL vs ALNY Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ALNY has a market cap of 33.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ALNY trades at $248.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ALNY's P/E ratio is 44.81. In terms of profitability, MDGL's ROE is -0.57%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, MDGL is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
MDGL vs ROIV Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ROIV has a market cap of 29.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ROIV trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ROIV's P/E ratio is -38.82. In terms of profitability, MDGL's ROE is -0.57%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, MDGL is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
MDGL vs INSM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, INSM has a market cap of 28B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while INSM trades at $129.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas INSM's P/E ratio is -31.49. In terms of profitability, MDGL's ROE is -0.57%, compared to INSM's ROE of -1.11%. Regarding short-term risk, MDGL is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
MDGL vs INCY Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while INCY trades at $121.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas INCY's P/E ratio is 16.33. In terms of profitability, MDGL's ROE is -0.57%, compared to INCY's ROE of +0.30%. Regarding short-term risk, MDGL is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
MDGL vs BNTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BNTX trades at $96.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BNTX's P/E ratio is -12.54. In terms of profitability, MDGL's ROE is -0.57%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, MDGL is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
MDGL vs UTHR Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, UTHR has a market cap of 21.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while UTHR trades at $497.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas UTHR's P/E ratio is 17.79. In terms of profitability, MDGL's ROE is -0.57%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, MDGL is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
MDGL vs BGNE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MDGL's ROE is -0.57%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, MDGL is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check BGNE's competition here
Genmab A/S (NASDAQ: GMAB)
MDGL vs GMAB Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, GMAB has a market cap of 19.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while GMAB trades at $32.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas GMAB's P/E ratio is 24.47. In terms of profitability, MDGL's ROE is -0.57%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, MDGL is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check GMAB's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
MDGL vs DNA-WT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MDGL's ROE is -0.57%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, MDGL is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
MDGL vs ASND Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ASND trades at $263.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ASND's P/E ratio is -108.89. In terms of profitability, MDGL's ROE is -0.57%, compared to ASND's ROE of +1.90%. Regarding short-term risk, MDGL is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
MDGL vs NBIX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while NBIX trades at $156.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas NBIX's P/E ratio is 22.57. In terms of profitability, MDGL's ROE is -0.57%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, MDGL is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
MDGL vs JAZZ Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while JAZZ trades at $245.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas JAZZ's P/E ratio is 9.16. In terms of profitability, MDGL's ROE is -0.57%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, MDGL is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
MDGL vs BBIO Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BBIO trades at $72.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BBIO's P/E ratio is -19.37. In terms of profitability, MDGL's ROE is -0.57%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, MDGL is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
MDGL vs EXEL Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while EXEL trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas EXEL's P/E ratio is 16.03. In terms of profitability, MDGL's ROE is -0.57%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, MDGL is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
MDGL vs SMMT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while SMMT trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas SMMT's P/E ratio is -15.67. In terms of profitability, MDGL's ROE is -0.57%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, MDGL is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
MDGL vs HALO Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while HALO trades at $107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas HALO's P/E ratio is 20.00. In terms of profitability, MDGL's ROE is -0.57%, compared to HALO's ROE of +1.81%. Regarding short-term risk, MDGL is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check HALO's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
MDGL vs BMRN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BMRN trades at $65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BMRN's P/E ratio is 31.58. In terms of profitability, MDGL's ROE is -0.57%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, MDGL is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
MDGL vs KRTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MDGL's ROE is -0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MDGL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
MDGL vs ARWR Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ARWR has a market cap of 11.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ARWR trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ARWR's P/E ratio is -36.82. In terms of profitability, MDGL's ROE is -0.57%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, MDGL is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
MDGL vs AXSM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while AXSM trades at $220.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas AXSM's P/E ratio is -57.64. In terms of profitability, MDGL's ROE is -0.57%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, MDGL is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check AXSM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
MDGL vs TECH Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TECH trades at $72.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TECH's P/E ratio is 37.18. In terms of profitability, MDGL's ROE is -0.57%, compared to TECH's ROE of +0.09%. Regarding short-term risk, MDGL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
MDGL vs RNAM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MDGL's ROE is -0.57%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MDGL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check RNAM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
MDGL vs KRYS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while KRYS trades at $347.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas KRYS's P/E ratio is 43.48. In terms of profitability, MDGL's ROE is -0.57%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MDGL is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
MDGL vs RXDX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MDGL's ROE is -0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MDGL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
MDGL vs PTGX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PTGX trades at $148.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PTGX's P/E ratio is 143.86. In terms of profitability, MDGL's ROE is -0.57%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, MDGL is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
MDGL vs KYMR Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while KYMR trades at $114.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas KYMR's P/E ratio is -35.92. In terms of profitability, MDGL's ROE is -0.57%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, MDGL is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check KYMR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
MDGL vs PRAX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PRAX trades at $334.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PRAX's P/E ratio is -25.88. In terms of profitability, MDGL's ROE is -0.57%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, MDGL is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PRAX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
MDGL vs CYTK Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CYTK trades at $73.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CYTK's P/E ratio is -10.22. In terms of profitability, MDGL's ROE is -0.57%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, MDGL is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
MDGL vs NUVL Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MDGL's ROE is -0.57%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MDGL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check NUVL's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
MDGL vs IONS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while IONS trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas IONS's P/E ratio is -31.52. In terms of profitability, MDGL's ROE is -0.57%, compared to IONS's ROE of -1.11%. Regarding short-term risk, MDGL is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
MDGL vs CRNX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CRNX's P/E ratio is -16.86. In terms of profitability, MDGL's ROE is -0.57%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MDGL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
MDGL vs IMGN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MDGL's ROE is -0.57%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MDGL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
MDGL vs ABVX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ABVX trades at $118.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ABVX's P/E ratio is -62.19. In terms of profitability, MDGL's ROE is -0.57%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MDGL is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ABVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
MDGL vs TXG Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TXG has a market cap of 8.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TXG trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TXG's P/E ratio is -116.25. In terms of profitability, MDGL's ROE is -0.57%, compared to TXG's ROE of -0.09%. Regarding short-term risk, MDGL is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TXG's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
MDGL vs PCVX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PCVX trades at $59.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PCVX's P/E ratio is -7.79. In terms of profitability, MDGL's ROE is -0.57%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, MDGL is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
MDGL vs BPMC Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MDGL's ROE is -0.57%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MDGL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
MDGL vs APGE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas APGE's P/E ratio is -31.19. In terms of profitability, MDGL's ROE is -0.57%, compared to APGE's ROE of -0.30%. Regarding short-term risk, MDGL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
MDGL vs IBRX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while IBRX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas IBRX's P/E ratio is -8.15. In terms of profitability, MDGL's ROE is -0.57%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, MDGL is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
MDGL vs TGTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TGTX trades at $53.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TGTX's P/E ratio is 19.53. In terms of profitability, MDGL's ROE is -0.57%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, MDGL is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
MDGL vs CERE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CERE's P/E ratio is -16.47. In terms of profitability, MDGL's ROE is -0.57%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MDGL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
MDGL vs TWST Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TWST has a market cap of 7.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TWST trades at $127.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TWST's P/E ratio is -57.31. In terms of profitability, MDGL's ROE is -0.57%, compared to TWST's ROE of -0.30%. Regarding short-term risk, MDGL is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
MDGL vs SYRE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while SYRE trades at $90.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas SYRE's P/E ratio is -46.46. In terms of profitability, MDGL's ROE is -0.57%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, MDGL is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
MDGL vs IMVT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while IMVT trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas IMVT's P/E ratio is -13.25. In terms of profitability, MDGL's ROE is -0.57%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, MDGL is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
MDGL vs MTSR Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MDGL's ROE is -0.57%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MDGL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
MDGL vs RYTM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RYTM trades at $104.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RYTM's P/E ratio is -33.67. In terms of profitability, MDGL's ROE is -0.57%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, MDGL is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
MDGL vs BLTE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while BLTE trades at $173.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas BLTE's P/E ratio is -92.94. In terms of profitability, MDGL's ROE is -0.57%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, MDGL is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
MDGL vs CAI Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CAI trades at $24.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CAI's P/E ratio is 68.39. In terms of profitability, MDGL's ROE is -0.57%, compared to CAI's ROE of +0.19%. Regarding short-term risk, MDGL is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CAI's competition here
Merus N.V. (NASDAQ: MRUS)
MDGL vs MRUS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MDGL's ROE is -0.57%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MDGL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
MDGL vs ACLX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MDGL's ROE is -0.57%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MDGL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
MDGL vs SRRK Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while SRRK trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas SRRK's P/E ratio is -16.06. In terms of profitability, MDGL's ROE is -0.57%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, MDGL is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
MDGL vs RETA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RETA's P/E ratio is -66.29. In terms of profitability, MDGL's ROE is -0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MDGL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check RETA's competition here
CG Oncology Inc. (NASDAQ: CGON)
MDGL vs CGON Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CGON trades at $72.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CGON's P/E ratio is -26.90. In terms of profitability, MDGL's ROE is -0.57%, compared to CGON's ROE of -0.25%. Regarding short-term risk, MDGL is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
MDGL vs CNTA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MDGL's ROE is -0.57%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MDGL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
MDGL vs TVTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TVTX trades at $66.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TVTX's P/E ratio is -147.04. In terms of profitability, MDGL's ROE is -0.57%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, MDGL is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
MDGL vs MIRM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MIRM trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MIRM's P/E ratio is -6.75. In terms of profitability, MDGL's ROE is -0.57%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, MDGL is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
MDGL vs DNTH Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while DNTH trades at $106.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas DNTH's P/E ratio is -25.59. In terms of profitability, MDGL's ROE is -0.57%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, MDGL is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
MDGL vs COGT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while COGT trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas COGT's P/E ratio is -15.83. In terms of profitability, MDGL's ROE is -0.57%, compared to COGT's ROE of -0.73%. Regarding short-term risk, MDGL is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
MDGL vs LGND Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while LGND trades at $284.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas LGND's P/E ratio is 31.23. In terms of profitability, MDGL's ROE is -0.57%, compared to LGND's ROE of +0.20%. Regarding short-term risk, MDGL is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
MDGL vs XENE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while XENE trades at $58.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas XENE's P/E ratio is -12.48. In terms of profitability, MDGL's ROE is -0.57%, compared to XENE's ROE of -0.44%. Regarding short-term risk, MDGL is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check XENE's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
MDGL vs CDTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MDGL's ROE is -0.57%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MDGL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CDTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
MDGL vs ORKA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ORKA trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ORKA's P/E ratio is -47.62. In terms of profitability, MDGL's ROE is -0.57%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, MDGL is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ORKA's competition here
Abcam plc (NASDAQ: ABCM)
MDGL vs ABCM Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MDGL's ROE is -0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MDGL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ABCM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
MDGL vs PTCT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PTCT trades at $66.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PTCT's P/E ratio is -28.35. In terms of profitability, MDGL's ROE is -0.57%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, MDGL is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PTCT's competition here
Erasca, Inc. (NASDAQ: ERAS)
MDGL vs ERAS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ERAS trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ERAS's P/E ratio is -17.08. In terms of profitability, MDGL's ROE is -0.57%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, MDGL is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ERAS's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
MDGL vs ISEE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MDGL's ROE is -0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MDGL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
MDGL vs APLS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas APLS's P/E ratio is 38.35. In terms of profitability, MDGL's ROE is -0.57%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MDGL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
MDGL vs DFTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while DFTX trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas DFTX's P/E ratio is N/A. In terms of profitability, MDGL's ROE is -0.57%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, MDGL is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check DFTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
MDGL vs CRSP Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CRSP trades at $51.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CRSP's P/E ratio is -10.87. In terms of profitability, MDGL's ROE is -0.57%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, MDGL is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
MDGL vs EWTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while EWTX trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas EWTX's P/E ratio is -24.00. In terms of profitability, MDGL's ROE is -0.57%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, MDGL is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
MDGL vs TERN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TERN's P/E ratio is -51.41. In terms of profitability, MDGL's ROE is -0.57%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MDGL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
MDGL vs ACAD Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ACAD trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ACAD's P/E ratio is 12.54. In terms of profitability, MDGL's ROE is -0.57%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, MDGL is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ACAD's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
MDGL vs FOLD Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MDGL's ROE is -0.57%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MDGL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
MDGL vs AKRO Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MDGL's ROE is -0.57%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MDGL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
MDGL vs ALPN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MDGL's ROE is -0.57%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MDGL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
MDGL vs PBLS Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PBLS trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PBLS's P/E ratio is -41.91. In terms of profitability, MDGL's ROE is -0.57%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, MDGL is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
MDGL vs OPT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas OPT's P/E ratio is -1.52. In terms of profitability, MDGL's ROE is -0.57%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MDGL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
MDGL vs PRTC Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas PRTC's P/E ratio is -3.78. In terms of profitability, MDGL's ROE is -0.57%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, MDGL is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check PRTC's competition here
Veradermics, Incorporated (NYSE: MANE)
MDGL vs MANE Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MANE trades at $98.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MANE's P/E ratio is -31.52. In terms of profitability, MDGL's ROE is -0.57%, compared to MANE's ROE of -0.38%. Regarding short-term risk, MDGL is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
MDGL vs RLAY Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RLAY trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RLAY's P/E ratio is -12.02. In terms of profitability, MDGL's ROE is -0.57%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, MDGL is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
MDGL vs MRTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MDGL's ROE is -0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MDGL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
MDGL vs CELC Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CELC trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CELC's P/E ratio is -19.41. In terms of profitability, MDGL's ROE is -0.57%, compared to CELC's ROE of -3.51%. Regarding short-term risk, MDGL is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
MDGL vs ELVN Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ELVN trades at $54.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ELVN's P/E ratio is -32.53. In terms of profitability, MDGL's ROE is -0.57%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, MDGL is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ELVN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
MDGL vs ADPT Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while ADPT trades at $24.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas ADPT's P/E ratio is -59.02. In terms of profitability, MDGL's ROE is -0.57%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, MDGL is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
MDGL vs TNGX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TNGX trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TNGX's P/E ratio is -28.65. In terms of profitability, MDGL's ROE is -0.57%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, MDGL is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
MDGL vs CPRX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CPRX's P/E ratio is 12.30. In terms of profitability, MDGL's ROE is -0.57%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MDGL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CPRX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
MDGL vs IOVA Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while IOVA trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas IOVA's P/E ratio is -11.78. In terms of profitability, MDGL's ROE is -0.57%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, MDGL is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check IOVA's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
MDGL vs TLX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while TLX trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas TLX's P/E ratio is 117.85. In terms of profitability, MDGL's ROE is -0.57%, compared to TLX's ROE of +0.07%. Regarding short-term risk, MDGL is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
MDGL vs RYZB Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MDGL's ROE is -0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MDGL is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check RYZB's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
MDGL vs VKTX Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while VKTX trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas VKTX's P/E ratio is -6.86. In terms of profitability, MDGL's ROE is -0.57%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, MDGL is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for MDGL.Check VKTX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
MDGL vs CBAY Comparison September 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $534.49 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.76, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MDGL's ROE is -0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MDGL is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for MDGL.Check CBAY's competition here